Recent notable negative changes in fundamentals have impacted Medifast Inc. (NYSE: MED): significant quarterly sales deceleration occurred, the consensus estimate for December, 2024 decreased significantly, and the consensus estimate for December, 2025 decreased significantly.
Medifast Inc. (NYSE: MED) suffers from notable negative changes in investment behavior: the stock fell on very heavy volume.
In light of these highly negative signals we are reviewing our current Overall Rating of F. We would continue to view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
MED’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be a Value Builder.
Medifast has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects complementary signals from PTR’s two proprietary measures of a stock’s attractiveness. Medifast has a slightly negative Appreciation Score of 36 and a very low Power Rating of 0, with the Lowest Value Trend Rating the result.
Recent Price Action
Medifast Inc. (NYSE: MED) stock closed at $22.02 on 6/5/24 after a large decline of -8.1%. Moreover, exceptionally high trading volume at 243% of normal accompanied the decline. The stock has declined -11.2% during the last week and has been extremely weak relative to the market over the last nine months.
Be the first to comment